J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, vol.136, pp.359-86, 2015.

Y. Tang, Y. Wang, M. F. Kiani, and B. Wang, Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer, Clin Breast Cancer, vol.16, pp.335-378, 2016.

R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, vol.65, pp.5-29, 2015.

M. Sundquist, L. Brudin, and G. Tejler, Improved survival in metastatic breast cancer 1985-2016, Breast, vol.31, pp.46-50, 2017.

C. K. Osborne and R. Schiff, Mechanisms of endocrine resistance in breast cancer, Annu Rev Med, vol.62, pp.233-280, 2011.

M. J. Higgins and J. Baselga, Targeted therapies for breast cancer, J Clin Invest, vol.121, pp.3797-803, 2011.

W. D. Foulkes, I. E. Smith, and J. S. Reis-filho, Triple-negative breast cancer, N Engl J Med, vol.363, pp.1938-1986, 2010.
URL : https://hal.archives-ouvertes.fr/hal-02463255

C. M. Perou, T. Sørlie, M. B. Eisen, M. Van-de-rijn, S. S. Jeffrey et al., Molecular portraits of human breast tumours, Nature, vol.406, pp.747-52, 2000.

T. Sørlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A, vol.98, pp.10869-74, 2001.

T. Sorlie, R. Tibshirani, J. Parker, T. Hastie, J. S. Marron et al., Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci U S A, vol.100, pp.8418-8441, 2003.

A. Goldhirsch, E. P. Winer, A. S. Coates, R. D. Gelber, M. Piccart-gebhart et al., Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, Ann Oncol, vol.24, pp.2206-2229, 2013.

C. M. Perou, Molecular stratification of triple-negative breast cancers, Oncologist, vol.16, pp.61-70, 2011.

A. R. Green, D. G. Powe, E. A. Rakha, D. Soria, C. Lemetre et al., Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers

, Br J Cancer, vol.109, pp.1886-94, 2013.

E. A. Rakha, D. Soria, A. R. Green, C. Lemetre, D. G. Powe et al., Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer, Br J Cancer, vol.110, pp.1688-97, 2014.

K. M. Mcnamara, N. L. Moore, T. E. Hickey, H. Sasano, and W. D. Tilley, Complexities of androgen receptor signalling in breast cancer, Endocr Relat Cancer, vol.21, pp.161-81, 2014.

P. Farmer, H. Bonnefoi, V. Becette, M. Tubiana-hulin, P. Fumoleau et al., Identification of molecular apocrine breast tumours by microarray analysis, Oncogene, vol.24, pp.4660-71, 2005.

J. Lehmann-che, A. S. Hamy, R. Porcher, M. Barritault, F. Bouhidel et al., Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15, Breast Cancer Res, vol.15, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00850498

M. Guedj, L. Marisa, A. De-reynies, B. Orsetti, R. Schiappa et al., A refined molecular taxonomy of breast cancer, Oncogene, vol.31, pp.1196-206, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00611752

B. D. Lehmann, J. A. Bauer, X. Chen, M. E. Sanders, A. B. Chakravarthy et al., Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J Clin Invest, vol.19, pp.2750-67, 2011.

L. J. Van-'t-veer, H. Dai, M. J. Van-de-vijver, Y. D. He, A. A. Hart et al., Gene expression profiling predicts clinical outcome of breast cancer, Nature, vol.415, pp.530-566, 2002.

C. K. Ng, A. M. Schultheis, F. C. Bidard, B. Weigelt, and J. S. Reis-filho, Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights, J Natl Cancer Inst, vol.107, 2015.

M. J. Van-de-vijver, Y. D. He, L. J. Van't-veer, H. Dai, A. A. Hart et al., A geneexpression signature as a predictor of survival in breast cancer, N Engl J Med, vol.347, pp.1999-2009, 2002.

S. Paik, S. Shak, G. Tang, C. Kim, J. Baker et al., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, vol.351, pp.2817-2843, 2004.

J. S. Parker, M. Mullins, M. C. Cheang, S. Leung, D. Voduc et al., Supervised risk predictor of breast cancer based on intrinsic subtypes, J Clin Oncol, vol.27, pp.1160-67, 2009.

M. Dowsett, I. Sestak, E. Lopez-knowles, K. Sidhu, A. K. Dunbier et al., Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy, J Clin Oncol, vol.31, pp.2783-90, 2013.

L. N. Harris, N. Ismaila, L. M. Mcshane, F. Andre, D. E. Collyar et al., Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer, J Clin Oncol, vol.34, pp.1134-50, 2016.

C. Sotiriou, S. Y. Neo, L. M. Mcshane, E. L. Korn, P. M. Long et al., Breast cancer classification and prognosis based on gene expression profiles from a population-based study, Proc Natl Acad Sci U S A, vol.100, pp.10393-98, 2003.

E. A. Rakha and A. R. Green, Molecular classification of breast cancer: what the pathologist needs to know, Pathology, vol.49, pp.111-130, 2017.

J. A. Sparano, R. J. Gray, D. F. Makower, K. I. Pritchard, K. S. Albain et al., Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer, N Engl J Med, vol.379, pp.111-132, 2018.

E. J. Blok, E. Bastiaannet, W. B. Van-den-hout, G. J. Liefers, V. T. Smit et al., Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe, Cancer Treat Rev, vol.62, pp.74-90, 2018.

S. Li, D. Shen, J. Shao, R. Crowder, W. Liu et al., Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts, Cell Rep, vol.4, pp.1116-1146, 2013.

D. R. Robinson, Y. M. Wu, P. Vats, F. Su, R. J. Lonigro et al., Activating ESR1 mutations in hormone-resistant metastatic breast cancer, Nat Genet, vol.45, pp.1446-51, 2013.

E. A. Rakha, J. S. Reis-filho, and E. Io, Combinatorial biomarker expression in breast cancer, Breast Cancer Res Treat, vol.120, pp.293-308, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00535436

S. Lal, M. Reed, A. E. De-luca, X. M. Simpson, and P. T. , Molecular signatures in breast cancer, Methods, vol.131, pp.135-181, 2017.

A. C. Wolff, M. E. Hammond, D. G. Hicks, M. Dowsett, L. M. Mcshane et al., Recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J Clin Oncol, vol.31, pp.3997-4013, 2013.

, American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 2017.

M. Elbouchtaoui, I. Tengher, C. Miquel, C. Brugière, A. Benbara et al., Micromolecular methods for diagnosis and therapeutic strategy: a case study, Oncotarget, vol.9, pp.22862-69, 2018.

P. Belgrader, S. C. Tanner, J. F. Regan, R. Koehler, B. J. Hindson et al., Droplet digital PCR measurement of HER2 copy number alteration in formalin-fixed paraffinembedded breast carcinoma tissue, Clin Chem, 2013.

, , vol.59, pp.991-94

Y. Zhu, D. Lu, M. E. Lira, Q. Xu, Y. Du et al., Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples, Exp Mol Pathol, vol.100, pp.287-93, 2016.

J. Lehmann-che, A. -. Bouhidel, F. Turpin, E. Antoine, M. Soliman et al., Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches, Br J Cancer, vol.104, pp.1739-1785, 2011.

C. F. Singer, Y. Y. Tan, F. Fitzal, G. G. Steger, D. Egle et al., Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer, Clin Cancer Res, vol.23, pp.3676-83, 2017.

H. Masuda, K. A. Baggerly, Y. Wang, Y. Zhang, A. M. Gonzalez-angulo et al., Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes, Clin Cancer Res, vol.19, pp.5533-5573, 2013.

W. De-roock, B. Claes, D. Bernasconi, D. Schutter, J. Biesmans et al., Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, Lancet Oncol, vol.11, issue.10, pp.70130-70133, 2010.

H. S. Park, M. H. Jang, E. J. Kim, H. J. Kim, H. J. Lee et al., High EGFR gene copy number predicts poor outcome in triple-negative breast cancer, Mod Pathol, vol.27, pp.1212-1234, 2014.

A. Gucalp, S. Tolaney, S. J. Isakoff, J. N. Ingle, M. C. Liu et al., Phase II trial of bicalutamide in patients with androgen receptorpositive, estrogen receptor-negative metastatic Breast Cancer, Clin Cancer Res, vol.19, pp.5505-5517, 2013.

H. Bonnefoi, T. Grellety, O. Tredan, M. Saghatchian, F. Dalenc et al., A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1), Ann Oncol, vol.27, pp.812-830, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01791274

G. Bousquet, J. P. Feugeas, I. Ferreira, L. Vercellino, J. N. Bertheau et al., Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma, Breast Cancer Res, vol.16, p.401, 2014.

T. T. Nguyen, E. Bouchtaoui, M. Feugeas, J. P. Vercillino, L. De-bazelaire et al., Individual xenografts for personalized treatment of women with metastatic triple negative breast cancer, Journal of Translational Genetics and Genomics, vol.2, p.19, 2018.

G. Bousquet, E. Bouchtaoui, M. Leboeuf, C. Battistella, M. Varna et al., Tracking sub-clonal TP53 mutated tumor cells in human metastatic renal cell carcinoma, Oncotarget, vol.6, pp.19279-89, 2015.

M. C. Haffner, T. Mosbruger, D. M. Esopi, H. Fedor, C. M. Heaphy et al., Tracking the clonal origin of lethal prostate cancer, J Clin Invest, vol.123, pp.4918-4940, 2013.

K. Otsuji, T. Sasaki, A. Tanaka, A. Kunita, M. Ikemura et al., Use of droplet digital PCR for quantitative and automatic analysis of the HER2 status in breast cancer patients, Breast Cancer Res Treat, vol.162, pp.11-18, 2017.

X. Wang, Y. Wu, X. Song, C. Sun, C. Wu et al., Human epidermal growth factor receptor 2 amplification detection by droplet digital polymerase chain reaction in formalinfixed paraffin-embedded breast and gastric cancer samples, J Cancer Res Ther, vol.13, pp.730-764, 2017.

C. De-bazelaire, A. Coffin, S. Cohen, A. Scemama, and E. De-kerviler, Biopsies in oncology. Diagn Interv Imaging, vol.95, pp.647-57, 2014.

C. Lefebvre, T. Bachelot, T. Filleron, M. Pedrero, M. Campone et al., Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis, PLoS Med, vol.13, p.1002201, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02297451

E. Furet, E. Bouchtaoui, M. Feugeas, J. P. Miquel, C. Leboeuf et al., Increased risk of brain metastases in women with breast cancer and p16 expression in metastatic lymph-nodes, Oncotarget, vol.8, pp.37332-37373, 2017.

, NCCN NCCN. Genetic/familial high-risk assessmentfor: breast and ovarian (Version 2, p.56, 2019.

, Quels gènes analyser face à un risque de cancer héréditaire du sein et de l'ovaire? 58. UNICANCER. Recommandations de prévention ou dépistage des personnes porteuses d'une mutation d

M. Bahassi and P. J. Stambrook, Next-generation sequencing technologies: breaking the sound barrier of human genetics, Mutagenesis, vol.29, pp.303-313, 2014.

, Comprehensive molecular portraits of human breast tumours, Nature, vol.490, pp.61-70, 2012.

A. M. Gonzalez-angulo, K. M. Timms, S. Liu, H. Chen, J. K. Litton et al., Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer, Clin Cancer Res, vol.17, pp.1082-89, 2011.

J. Peto, N. Collins, R. Barfoot, S. Seal, W. Warren et al., Prevalence of BRCA1 and BRCA2 gene mutations in patients with earlyonset breast cancer, J Natl Cancer Inst, vol.91, pp.943-992, 1999.

G. Rigakos and E. Razis, BRCAness: finding the Achilles heel in ovarian cancer, Oncologist, vol.17, pp.956-62, 2012.

J. Leidy, A. Khan, and D. Kandil, Basal-like breast cancer: update on clinicopathologic, immunohistochemical, and molecular features, Arch Pathol Lab Med, vol.138, pp.37-43, 2014.

N. Turner, A. Tutt, and A. Ashworth, Hallmarks of 'BRCAness' in sporadic cancers, Nat Rev Cancer, vol.4, pp.814-833, 2004.

M. Robson, S. A. Im, E. Senkus, B. Xu, S. M. Domchek et al., Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation, N Engl J Med, vol.377, pp.523-556, 2017.

A. S. Zimmer, M. Gillard, S. Lipkowitz, and J. M. Lee, Update on PARP Inhibitors in Breast Cancer, Curr Treat Options Oncol, vol.19, 2018.

K. Michailidou, P. Hall, A. Gonzalez-neira, M. Ghoussaini, J. Dennis et al., Large-scale genotyping identifies 41 new loci associated with breast cancer risk, Nat Genet, vol.45, pp.361-362, 2013.

K. Michailidou, J. Beesley, S. Lindstrom, S. Canisius, J. Dennis et al., Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer, Nat Genet, vol.47, pp.373-80, 2015.

A. B. Moffa and S. P. Ethier, Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells, J Cell Physiol, vol.210, pp.720-751, 2007.

N. Ahmadiyeh, M. M. Pomerantz, C. Grisanzio, P. Herman, L. Jia et al., 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC, Proc Natl Acad Sci U S A, vol.107, pp.9742-9788, 2010.

A. C. Antoniou, P. D. Pharoah, G. Mcmullan, N. E. Day, B. A. Ponder et al., Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study, Genet Epidemiol, vol.21, pp.1-18, 2001.

C. Curtis, S. P. Shah, S. F. Chin, G. Turashvili, O. M. Rueda et al., The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups, Nature, vol.486, pp.346-52, 2012.

M. Filipits, M. Rudas, R. Jakesz, P. Dubsky, F. Fitzal et al., A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors, Clin Cancer Res, vol.17, pp.6012-6032, 2011.

X. J. Ma, R. Salunga, S. Dahiya, W. Wang, E. Carney et al., A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer, Clin Cancer Res, vol.14, pp.2601-2609, 2008.

Y. Wang, J. G. Klijn, Y. Zhang, A. M. Sieuwerts, M. P. Look et al.,

, Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer, Lancet, vol.365, pp.671-79, 2005.

O. Krijgsman, P. Roepman, W. Zwart, J. S. Carroll, S. Tian et al., A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response, Breast Cancer Res Treat, vol.133, pp.37-47, 2012.

B. Weigelt, A. M. Glas, L. F. Wessels, A. T. Witteveen, J. L. Peterse et al., Gene expression profiles of primary breast www.oncotarget.com tumors maintained in distant metastases, Proc Natl Acad Sci U S A, vol.100, pp.15901-15906, 2003.

C. Wang, V. V. Iakovlev, V. Wong, S. Leung, K. Warren et al., Genomic alterations in primary breast cancers compared with their sentinel and more distal lymph node metastases: an aCGH study, Genes Chromosomes Cancer, vol.48, pp.1091-101, 2009.

M. M. Desouki, S. Liao, H. Huang, J. Conroy, N. J. Nowak et al., Identification of metastasis-associated breast cancer genes using a highresolution whole genome profiling approach, J Cancer Res Clin Oncol, vol.137, pp.795-809, 2011.

D. W. Craig, J. A. Shaughnessy, J. A. Kiefer, J. Aldrich, S. Sinari et al., Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities, Mol Cancer Ther, vol.12, pp.104-120, 2013.

J. Y. Lee, K. Park, S. H. Lim, H. S. Kim, K. H. Yoo et al., Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer, Oncotarget, vol.6, pp.43731-43773, 2015.

W. Onstenk, A. M. Sieuwerts, M. Weekhout, B. Mostert, E. A. Reijm et al., Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer, Cancer Lett, vol.362, pp.36-44, 2015.

J. Mcbryan, A. Fagan, D. Mccartan, F. T. Bane, D. Vare?lija et al., Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy, Clin Cancer Res, vol.21, pp.5371-79, 2015.

J. E. Lang, J. H. Scott, D. M. Wolf, P. Novak, V. Punj et al., Expression profiling of circulating tumor cells in metastatic breast cancer, Breast Cancer Res Treat, vol.149, pp.121-152, 2015.

S. Kimbung, I. Johansson, A. Danielsson, S. Veerla, E. Brage et al., Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer, Clin Cancer Res, vol.22, pp.146-57, 2016.

D. Fumagalli, T. R. Wilson, R. Salgado, X. Lu, J. Yu et al., Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers, Ann Oncol, vol.27, pp.1860-66, 2016.

N. Petrucelli, M. B. Daly, and T. Pal, BRCA1-and BRCA2-Associated Hereditary Breast and Ovarian Cancer, 1993.

, Online Mendelian Inheritance in Man OJHU, 2018.

, Online Mendelian Inheritance in Man OJHU, vol.600185

V. Viassolo, A. Ayme, and P. O. Chappuis, Cancer du sein : risque génétique, Imag Femme, vol.26, pp.95-104, 2016.

, Online Mendelian Inheritance in Man OJHU

K. Schneider, K. Zelley, K. E. Nichols, J. Garber, and . Li-fraumeni-syndrome, GeneReviews((R)). (, 1993.

, Online Mendelian Inheritance in Man OJHU, 2018.

P. Kaurah and D. G. Huntsman, Hereditary Diffuse Gastric Cancer, 1993.

O. Online-mendelian-inheritance-in-man, M. D. Baltimore, and . Number, , 2018.

C. Eng, . Pten-hamartoma-tumor, and . Syndrome, , 1993.

, Online Mendelian Inheritance in Man OJHU, 2018.

P. A. Mehta, J. Tolar, and . Fanconi-anemia, , 1993.

, Online Mendelian Inheritance in Man OJHU

V. Sopik, M. R. Akbari, S. A. Narod, E. R. Thompson, S. E. Boyle et al., Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients, Clin Genet, vol.88, pp.95-99, 2012.

L. M. Pelttari, J. I. Kiiski, S. Ranta, S. Vilske, C. Blomqvist et al., RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families, Springerplus, vol.4, p.92, 2015.

Z. Kleibl and V. N. Kristensen, Women at high risk of breast cancer: molecular characteristics, clinical presentation and management, Breast, vol.28, pp.136-180, 2016.

, Online Mendelian Inheritance in Man OJHU

W. Kohlmann, S. B. Gruber, and . Lynch-syndrome, , 1993.

, Online Mendelian Inheritance in Man OJHU, 2018.

O. Online-mendelian-inheritance-in-man, M. D. Baltimore, and . Number,

, Online Mendelian Inheritance in Man OJHU, 2018.

, Online Mendelian Inheritance in Man OJHU, vol.600259, pp.12-27

, Online Mendelian Inheritance in Man OJHU